New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti- Mycobacterium tuberculosis agents. by Monge, A. (Antonio) et al.
Graphical Abstract: 
 
36 new amide quinoxaline 1,4-di-N-oxide derivatives have been synthesized and 
evaluated as potential anti-tubercular agents by the TAACF, obtaining biological values 
in the same order as the reference compound rifampin. 
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 Abstract: 
 
Mycobacterium tuberculosis (M.Tb) is a bacillus capable of causing a chronic and fatal 
condition in humans known as tuberculosis (TB). It is estimated that there are 8 million new cases 
of TB per year and 3.1 million infected people die annually. Thirty-six new amide quinoxaline 1,4-
di-N-oxide derivatives have been synthesized and evaluated as potential anti-tubercular agents, 
obtaining biological values similar to the reference compound, Rifampin (RIF). 
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 1. Introduction 
 
Tuberculosis (TB) is a respiratory disease mainly caused by the bacillus Mycobacterium 
tuberculosis (M.Tb.). It is responsible for 8 million new cases and 3.1 million deaths per year, 
mostly occurring in developing countries, although there are over 400,000 new cases annually in 
industrialized countries. As infection with human immunodeficiency virus (HIV) becomes more 
prevalent, tuberculosis is becoming a serious problem in developed countries as well
1
, as can be 
observed in Figure 1. Of particular concern is the development of drug-resistant forms of the 
disease, Multidrug-Resistant Tuberculosis (MDR-TB) and Extensively Drug-Resistant Tuberculosis 
(XDR-TB). These forms of the disease are more often fatal and are difficult and expensive to treat. 
It has been estimated that up to 50 million people are infected with drug-resistant forms of TB.
2,3
 
Due to the problems related to MDR-TB and XDR-TB, it is necessary to develop new, potent, 
fast-acting anti-tuberculosis drugs with low-toxicity profiles that can be given in conjunction with 
drugs used to treat HIV infections.
4,5
 New drugs and improved delivery methods will be integral 
parts of a strategy to fully control future outbreaks of TB, particularly MDR-TB, which has severely 
challenged the limited number of effective treatment options.
3
 
 
Figure 1:  
 
Quinoxaline and quinoxaline 1,4-di-N-oxide derivatives display excellent biological activities 
(antiviral, anticancer, antibacterial, anti-parasitic… etc.) with application in many different 
therapeutic areas.
6-8
 As a result of the anti-tuberculosis research project, our group has published 
several papers in which synthesis and biological activity assessments of a large number of 
quinoxaline and quinoxaline 1,4-di-N-oxide derivatives have been described
9-17
,
 
identifying some 
structural requirements for optimal activity.
13-19
 
A few years ago, a group of thirty-one 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide 
derivatives were prepared and tested against M.Tb., obtaining some interesting results.
13
 Three of 
these compounds presented enough selectivity and good results in macrophage assay so as to merit 
continuation of their study. With the aim of improving the previous results, new amide quinoxaline 
1,4-di-N-oxide derivatives have been synthesized and evaluated as potential anti-tubercular agents, 
obtaining excellent results as can be observed in this report.  
 
2. Results and Discussion 
 
Thirty-six new 1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid aryl amide derivatives 
were prepared through the synthetic route as follows: 
First, the starting benzofuroxanes (BFX) were obtained by previously described methods.
20,21
 
Next, the initial β-acetoacetamide derivatives (1-4) were synthesized through acetoacetylation of 
corresponding aryl amines by diketene, using methanol as the solvent as shown in Scheme 1.
22
  
 
Scheme 1.  
 
Finally, the new 1,4-di-N-oxide-quinoxaline derivatives were prepared using a variation of the 
Beirut reaction, where the different BFX react with the corresponding β-acetoacetamide in the 
presence of calcium chloride and ethanolamine as catalysts (Scheme 2).
23
 
 
Scheme 2. 
 
Quinoxaline derivatives were un-substituted or substituted in positions 6 and 7 by chloro, fluoro 
or trifluoromethyl moiety as electron-withdrawing groups and by methyl or methoxy moiety as 
electron-releasing groups. When the new quinoxalines were prepared from monosubstituted-BFX, 
mixtures of positional isomers were obtained. Generally, it could be observed that the 7-substituted 
isomer prevailed over 6-substituted isomer.
24
  
Table 1 summarizes the biological values of the synthesized compounds. The primary screening 
level determines the activity of the compounds against M.Tb. in H37Rv strain. Samples showing a 
percentage of TB growth inhibition greater than or equal to 90% are considered active and 
therefore, move on to the secondary screening. Active compounds are tested in order to determine 
the actual minimum inhibitory concentration (MIC), and simultaneously cytotoxicity (IC50) in 
VERO cells is evaluated. Next, the MIC and IC50 values are formed into a ratio termed Selectivity 
Index (SI).  If the SI level is 10 or greater, a compound is considered active at the second level. 
 
Table 1:  
As can be observed in table 1, compounds 10 and 27 were identified as the most interesting 
derivatives, with great antitubercular activity and low values of cytotoxicity, as can be observed by 
their SI values. Derivatives 9, 13, 28, 29, 36 and 38 have also shown very good results. Some 
structure-activity relationships could be established.  
Looking at the values for compounds 9-13, 20-22, 27-31 and 36-40, it can be said that, in 
general, the introduction of an electron-withdrawing substituent in the quinoxaline ring results in an 
increment in the antitubercular activity of the derivatives. On the contrary, the insertion of an 
electro-releasing moiety results in a reduction of this activity, as can be observed by the results 
obtained for the compounds 6-8, 15-17, 24-26 and 33-35. In short, it can be concluded that the 
insertion of an electron-withdrawing moiety in the quinoxaline ring is an essential requirement in 
order to improve the antitubercular activity, as established in previous works reported by the 
group.
13
 
To further explore the SAR of these compounds, a methoxy group was substituted in the para 
position of the benzene ring. This derivatization led to an increase of the cytotoxicity of the 
compounds, as can be observed by comparing the following derivatives 5 vs 14, 6 vs 15, 11 vs 20, 
13 vs 22, 24 vs 33, 23 vs 32, 27 vs 36 and 29 vs 38. With the aim of improving these results, current 
studies are ongoing to modify not only the substituent on the benzene ring but also the aromatic ring 
itself.  
Finally, looking at the values of the compounds 10 vs 28 and 13 vs 31, it can be observed that 
lengthening the aliphatic chain can also result in a greater value of cytotoxicity. Taking into account 
these results and previous ones obtained by the group
13
, the most suitable linker is established as a 
single methylene group between the carboxamide and the benzene ring.
 
 
3. Conclusions 
 
Thirty-six new 1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid aryl amide derivatives 
were synthesized using a variation of the Beirut reaction. Thirty-four of these compounds were 
evaluated against M.Tb. in H37Rv strain; all of them showed a TB growth inhibition percentage 
greater than or equal to 90%.  These compounds were considered active at first level and moved on 
to the secondary screening, where the actual minimum inhibitory concentration (MIC) in H37Rv 
strain and cytotoxicity (IC50) in VERO cells were determined. In this case, twenty three of the 
twenty-six evaluated derivatives showed an SI greater than 10, being considered to be active at the 
second level.  
Taking into account the SI values shown in Table 1, it can be said that these values are similar to 
the reference compound, Rifampin (RIF). In conclusion, the potency, selectivity, and low 
cytotoxicity of these compounds make them valid leads for synthesizing new compounds that 
possess better activity. 
 
4. Experimental Section 
 
4.1. General Remarks 
 
All of the synthesized compounds were chemically characterized by thin layer chromatography 
(TLC), infrared (IR), proton nuclear magnetic resonance (
1
H-NMR) and elemental microanalyses 
(CHN). 
Alugram SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co. KG., Düren, 
Germany) was used for TLC, and Silica gel 60 (0.040-0.063 mm, Merck) was used for Flash 
Column Chromatography. The 
1
H MNR spectra were recorded on a Bruker 400 Ultrashield 
instrument (400 MHz), using TMS as internal standard and with DMSO-d6 or CDCl3 as solvents; 
the chemical shifts are reported in ppm (δ) and coupling constant (J) values are given in Hertz (Hz). 
Signal multiplicities are represented by: s (singlet), bs (broad singlet), d (doublet), dd (double 
doublet), ddd (double double doblet), t (triplet), q (quadruplet) and m (multiplet). The IR spectra 
were recorded on a Nicolet Nexus FTIR (Thermo, Madison, USA) in KBr pellets. Elemental 
microanalyses were obtained on a CHN-900 Elemental Analyzer (Leco, Tres Cantos, Spain) from 
vacuum-dried samples. The analytical results for C, H and N were within ± 0.4 of the theoretical 
values. Chemicals were purchased from Panreac Química S.A. (Barcelona, Spain), Sigma-Aldrich 
Química, S.A. (Alcobendas, Spain), Acros Organics (Janssen Pharmaceuticalaan, Geel, Belgium) 
and Lancaster (Bischheim-Strasbourg, France). 
 
4.2. General procedure of synthesis 
 
4.2.1. Synthesis of β-acetoacetamide derivatives (1-4) 
 
The corresponding aryl amines (20.0 mmol) were diluted in methanol (20.0 mL) in N2 
atmosphere and cooled in ice bath until 0ºC. Next, diketene (22.0 mmol) was added dropwise and 
the reaction was stirred for 2-3h. The obtained residue was precipitated with cold diethyl ether and 
filtered in order to obtain a red-brown solid. The compound was used without further purification. 
 
4.2.1.1. N-benzyl-3-oxobutanamide (1). Yield 25%. IR (KBr): 3318 (m, NH); 1617 (s, CO); 
1540 (s, CO). 
1
H MNR (400 MHz, CDCl3) δ ppm: 9.52 (bs, 1H, NH); 7.33-7.21 (m, 5H, Ph); 4.56-
4.35 (m, 4H, CH2-NH-CO-CH2-CO); 1.89 (s, 3H, CH3). 
 
4.2.1.2. N-(4-methoxybenzyl)-3-oxobutanamide (2). Yield 77%. IR (KBr): 3317 (s, NH); 
1619 (s, CO); 1539 (s, CO). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.46 (t, 1H, JNH-CH2=5.0 Hz, 
NH); 7.20 (d, 2H, JH2-H3=8.6 Hz, H2+H6); 6.89 (d, 2H, H3+H5); 4.22 (d, 2H, CH2-NH); 3.73 (s, 2H, 
CO-CH2-CO); 3.35 (s, 3H, OCH3); 2.15 (s, 3H, CH3). 
 
4.2.1.3. 3-Oxo-N-phenethylbutanamide (3). Yield 46%. IR (KBr): 3257 (s, NH); 1714 (s, 
CO); 1644 (s, CO). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.13 (t, 1H, JNH-CH2=5.2 Hz, NH); 7.34-
7.14 (m, 5H, Ph); 3.33-3.30 (m, 2H, CH2-NH); 3.27 (s, 2H, CO-CH2-CO); 2.72 (t, 2H, JCH2-Ph=7.2 
Hz, CH2-Ph); 2.10 (s, 3H, CH3). 
 
4.2.1.4. N-(4-methoxyphenethyl)-3-oxobutanamide (4). Yield 56%. IR (KBr): 3263 (m, NH); 
1719 (m, CO); 1641 (s, CO). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.10 (t, 1H, JNH-CH2=5.3 Hz, 
NH); 7.13 (d, 2H, JH2-H3=8.4 Hz, H2+H6); 6.85 (d, 2H, H3+H5); 3.72 (s, 3H, OCH3); 3.32-3.18 (m, 
4H, CH2-NH-CO-CH2-CO); 2.65 (t, 2H, JCH2-Ph=7.3 Hz, CH2-Ph); 2.10 (s, 3H, CH3). 
 
4.2.2. Synthesis of 1,4-di-N-oxide-3-methyl-quinoxaline-2-carboxylic acid aryl amide derivatives 
(5-40) 
 
The corresponding BFX (1.0 mmol) and the corresponding β-acetoacetamide (1.2 mmol) were 
dissolved in the minimum amount of methanol. Next, calcium chloride (0.1 mmol) and 
ethanolamine (5 drops) were added as catalyst, as described by Stumm and Niclas.
23
 The reaction 
was stirred at room temperature from 1 to 5 hours, filtered, and washed with cold ethanol. The solid 
was dissolved in dichloromethane and quenched with water. The organic phase was dried with 
sodium sulphate and filtered. The solvent was removed in vacuo and precipitated with cold diethyl 
ether in order to obtain a yellow solid. The solid was purified by column chromatography, if 
necessary. 
 
4.2.2.1. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (5). Yield: 
47%.  IR (KBr): 3218 (m, NH); 1677 (s, CO); 1324 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ 
ppm: 9.36 (t, 1H, JNH-CH2=5.8 Hz, NH); 8.52-8.49 (m, 2H, H5+H8); 8.02-7.95 (m, 2H, H6+H7); 7.46-
7.28 (m, 5H, Ph); 4.57 (d, 2H, CH2); 2.43 (s, 3H, CH3). Calculated analysis for C17H15N3O3: C: 
66.02%; H: 4.85%; N: 13.59%; Found: C: 66.02%; H: 4.96%; N: 13.69%. 
 
4.2.2.2. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-benzylamide (6).  
Yield: 1.3%. IR (KBr): 3222 (m, NH); 1661 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 9.37 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.39 (d, 1H, JH5-H6=8.8 Hz, H5); 8.31 (d, 1H, JH8-
H6=1.5 Hz, H8); 7.83 (dd, 1H, H6); 7.46-7.28 (m, 5H, Ph); 4.56 (d, 2H, CH2); 2.59 (s, 3H, CH3-C3); 
2.41 (s, 3H, CH3-C7). Calculated analysis for C18H17N3O3: C: 66.87%; H: 5.26%; N: 13.00%; Found: 
C: 66.79%; H: 5.26%; N: 12.91%. 
 
4.2.2.3. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-benzylamide (7).  
Yield: 21%. IR (KBr): 3199 (m, NH); 1679 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, CDCl3) δ 
ppm: 8.94 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.05 (s, 1H, H5); 7.98 (s, 1H, H8); 7.49-7.34 (m, 5H, Ph); 
4.67 (d, 2H, CH2); 2.65 (s, 3H, CH3-C3); 2.51 (s, 3H, CH3-C7); 2.48 (s, 3H, CH3-C6). Calculated 
analysis for C19H19N3O3: C: 67.66%; H: 5.64%; N: 12.46%; Found: C: 67.89%; H: 5.50%; N: 
12.45%. 
 
4.2.2.4. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (8).  
Yield: 8%. IR (KBr): 3276 (m, NH); 1655 (s, CO); 1323 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) 
δ ppm: 9.37 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.42 (d, 1H, JH5-H6=9.5 Hz, H5); 7.81 (d, 1H, JH8-H6=2.5 
Hz, H8); 7.60 (dd, 1H, H6); 7.47-7.28 (m, 5H, Ph); 4.56 (d, 2H, CH2); 4.00 (s, 3H, OCH3); 2.40 (s, 
3H, CH3). Calculated analysis for C18H17N3O4: C: 63.53%; H: 5.00%; N: 12.35%. Found: C: 
63.92%; H: 5.05%; N: 12.48%. 
 
4.2.2.5. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (9).  
Yield: 35%. IR (KBr): 3235 (m, NH); 1669 (s, CO); 1321 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 8.55-8.52 (m, 2H, H5+H8); 8.49 (t, 1H, JNH-CH2=5.7 Hz, NH); 7.81 (dd, 1H, JH6-H5=9.2 
Hz, JH6-H8=2.2 Hz, H6); 7.45-7.32 (m, 5H, Ph); 4.74 (d, 2H, CH2); 2.79 (s, 3H, CH3). Calculated 
analysis for C17H14ClN3O3: C: 59.38%; H: 4.07%; N: 12.23%; Found: C: 59.06%; H: 4.19%; N: 
12.13%. 
 
4.2.2.6. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide 
(10).  Yield: 61%. IR (KBr):  3274 (m, NH); 1649 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm: 8.72 (s, 1H, H5); 8.68 (s, 1H, H8); 8.41(t, 1H, JNH-CH2=5.8 Hz, NH); 7.44-7.32 
(m, 5H, Ph); 4.74 (d, 2H, CH2); 2.79 (s, 3H, CH3). Calculated analysis for C18H15Cl2N3O4: C: 
54.11%; H: 3.44%; N: 11.14%; Found: C: 54.08%; H: 3.38%; N: 10.87%. 
 
4.2.2.7. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (11).  
Yield: 45%. IR (KBr): 3300 (m, NH); 1671 (s, CO); 1323 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm:  8.61 (dd, 1H, JH5-H6=9.5 Hz, JH5-F=5.0 Hz, H5); 8.52 (d, 1H, JNH-CH2=5.7 Hz, NH); 8.19 
(dd, 1H, JH8-F=8.5 Hz, JH8-H6=2.7 Hz, H8); 7.62 (ddd, 1H, JH6-F=7.3 Hz,  H6); 7.46-7.28 (m, 5H, 
Ph); 4.74 (d, 2H, CH2); 2.77 (s, 3H, CH3). Calculated analysis for C17H14FN3O3: C: 62.37%; H: 
4.28%; N: 12.84%; Found: C: 62.28%; H: 4.32%; N: 12.96%.     
 
4.2.2.8. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide 
(12).  Yield: 38%. IR (KBr): 3292 (m, NH); 1670 (s, CO); 1529 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6): 9.38 (t, 1H, JNH-CH2=6.0 Hz, NH); 8.59-8.48 (m, 2H, H5+H8); 7.46-7.26 (m, 5H, Ph); 
4.56 (d, 2H, CH2); 2.42 (s, 3H, CH3). Calculated analysis for C17H13F2N3O3: C: 59.13%; H: 3.77%; 
N: 12.17%; Found: C: 59.36%; H: 3.62%; N: 11.90% 
 
4.2.2.9. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-
benzylamide (13).  Yield: 28%. IR (KBr): 3294(m, NH);  1670(s, CO); 1323 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.92 (d, 1H, JH8-H6=1.7 Hz, H8); 8.70 (d, 1H, JH5-H6=9.0 Hz, H5); 
8.38 (bs, 1H, NH); 8.03 (dd, 1H, H6); 7.45-7.32 (m, 5H, Ph); 4.75 (d, 2H, CH2); 2.82 (s, 3H, CH3). 
Calculated analysis for C18H14F3N3O3: C: 57.29%; H: 3.71%; N: 11.14%; Found: C: 57.25%; H: 
3.62%; N: 11.15%. 
 
4.2.2.10. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-methoxybenzyl)-amide 
(14). Yield: 82%.  IR (KBr): 3174 (m, NH); 1674 (f, CO); 1329 (f, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm: 9.26 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.52-8.50 (m, 2H, H8+H5); 8.02-7.95 (m, 2H, 
H6+H7); 7.37 (d, 2H, JH2’-H3’=8.7 Hz, H2’+H6’); 6.95 (d, 2H, H3’+H5’); 4.49 (d, 2H, CH2); 3.76 (s, 
3H, OCH3); 2.42 (s, 3H, CH3). Calculated analysis for C18H17N3O4: C: 63.71%; H: 5.05%; N: 
12.38%; Found: C: 63.43%; H: 5.11%; N: 12.03% 
 
4.2.2.11. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-(4-methoxybenzyl)-
amide (15).  Yield: 71%. IR (KBr): 3206 (m, NH); 1674 (f, CO); 1326 (f, N
+
O). 
1
H MNR (400 
MHz, DMSO-d6) δ ppm: 9.27 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.39 (d, 1H, JH5-H6=8.8 Hz, H5); 8.30 (s, 
1H, H8); 7.82 (dd, 1H, JH6-H8=1.7 Hz, H6); 7.36 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’), 6.94 (d, 2H, 
H3’+H5’), 4.48 (d, 2H, CH2), 3.76 (s, 3H, OCH3), 2.59 (s, 3H, CH3-C7), 2.39 (s, 3H, CH3-C3). 
Calculated analysis for C19H19N3O4: C: 64.58%; H: 5.42%; N: 11.89 %; Found: C: 64.83%; H: 
5.61%; N: 11.50%. 
 
4.2.2.12. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-(4-methoxybenzyl)-
amide (16).  Yield: 64%. IR (KBr): 3210 (m, NH); 1677 (f, CO); 1332 (f, N
+
O).
 1
H RMN (400 
MHz, DMSO-d6) δ ppm: 9.28 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.27 (s, 1H, H5); 8.25 (s, 1H, H8); 7.37 
(d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.94 (d, 2H, H3’+H5’); 4.48 (d, 2H, CH2); 3.76 (s, 3H, OCH3); 
2.50 (s, 6H, CH3-C6+CH3-C7); 2.39 (s, 3H, CH3-C3). Calculated analysis for C20H21N3O4: C: 65.38%; 
H: 5.76%; N: 11.44%; Found: C: 65.09%; H: 5.62%; N: 11.63%.  
 
4.2.2.13. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (17).  Yield: 79%. IR (KBr): 3283 (m, NH); 1652 (f, CO); 1329 (f, N
+
O). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 9.28 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.40 (d, 1H, JH5-H6=9.5 Hz, 
H5); 7.79 (d, 1H, JH8-H6=2.6 Hz, H8); 7.59 (dd, 1H, H6); 7.37 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.94 
(d, 2H, H3’+H5’); 4.48 (d, 2H, CH2), 3.99 (s, 3H, OCH3-C7), 3.75 (s, 3H, OCH3-C4’), 2.38 (s, 3H, 
CH3). Calculated analysis for C19H19N3O5: C: 61.78%; H: 5.18%; N: 11.38%; Found: 61.58%; H: 
5.21%; N: 11.32%. 
 
4.2.2.14. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (18).  Yield: 30%. IR (KBr): 3270 (m, NH); 1654 (f, CO); 1330 (f, N
+
O).
 1
H 
MNR (400 MHz, DMSO-d6): 9.27 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.53-8.47 (m, 2H, H5+H8); 8.03 
(dd, 1H, JH6-H5=9.2 Hz, JH6-H8=2.3 Hz, H6); 7.36 (d, 2H, JH2’-H3’=8.7 Hz, H2’+H6’); 6.94 (d, 2H, 
H3’+H5’); 4.48 (d, 2H, CH2); 3.76 (s, 3H, OCH3); 2.40 (s, 3H, CH3). Calculated analysis for 
C18H16ClN3O4: C: 57.84%; H: 4.31%; N: 11.24%; Found: C: 57.92%; H: 4.32%; N: 11.22%. 
 
4.2.2.15. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (19).  Yield: 18%. IR (KBr):  3199 (m, NH); 1643 (f, CO); 1323 (f, N
+
O).
 1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 9.30 (t, 1H, JNH-CH2=5.8 Hz, NH); 8.67 (s, 2H, H5+H8); 7.35 
(d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.94 (d, 1H, H3’+H5’), 4.48 (d, 2H, CH2), 3.75 (s, 3H, OCH3), 
2.40 (s, 3H, CH3). Calculated analysis for C18H15Cl2N3O4: C: 57.84%; H: 4.31%; N: 11.24%; 
Found: C: 57.92%; H: 4.32%; N: 11.22%. 
 
4.2.2.16. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (20).  Yield: 31%. IR (KBr): 3213 (m, NH); 1677 (f, CO); 1323 (f, N
+
O).
 1
H 
MNR (400 MHz, DMSO-d6) δ ppm:  9.28 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.57 (dd, 1H, JH5-H6=9.5 Hz, 
JH5-F=5.2 Hz, H5); 8.24 (dd, 1H, JH8-F=8.8, JH8-H6=2.8 Hz, H8); 7.92 (ddd, 1H, JH8-F=8.0 Hz, H6); 
7.36 (d, 2H, JH2’-H3’=8.7 Hz, H2’+H6’); 6.94 (d, 2H, H3’+H5’); 4.49 (d, 2H, CH2); 3.76 (s, 3H, 
OCH3); 2.40 (s, 3H, CH3). Calculated analysis for C18H16FN3O4: C: 60.50%; H: 4.51%; N: 11.76%; 
Found: C: 60.74%; H: 4.51%; N: 11.73%. 
 
4.2.2.17. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (21).  Yield: 71%. IR (KBr): 3199 (m, NH); 1645 (f, CO); 1333 (f, N
+
O). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 9.29 (t, 1H, JNH-CH2=5.8 Hz, NH); 8.56-8.50 (m, 2H, H5+H8); 
7.36 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.94 (d, 2H, H3’+H5’); 4.48 (d, 2H, CH2); 3.76 (s, 3H, 
OCH3); 2.41 (s, 3H, CH3). Calculated analysis for C18H15F2N3O4: C: 57.60%; H: 4.03%; N: 
11.20%; Found: C: 57.33%; H: 3.91%; N: 11.14%. 
 
4.2.2.18. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (22).  Yield: 78%. IR (KBr): 9.88%. IR (KBr): 3276 (m, NH); 1648 (f, CO); 
1133 (f, N
+
O). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 9.29 (t, 1H, JNH-CH2=6.1 Hz, NH); 8.75 (s, 
1H, H5); 8.70-8.69 (m, 1H, H8); 8.32-8.26 (m, 1H, H6); 7.36 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.95 
(d, 2H, H3’+H5’); 4.49 (d, 2H, CH2); 3.76 (s, 3H, OCH3); 2.44 (s, 3H, CH3). Calculated analysis for 
C19H16F3N3O4: C: 56.02%; H: 3.93%; N: 10.32%; Found: C: 56.39%; H: 3.85%; N: 10.44%. 
 
4.2.2.19. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-phenylethylamide (23). 
Yield: 55%. IR (KBr): 3213 (m, NH); 1668 (s, CO); 1334 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 8.91 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.50-8.45 (m, 2H, H5+H8); 8.02-7.95 (m, 2H, H6+H7); 
7.35-7.22 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph), 2.25 (s, 
3H, CH3). Calculated analysis for C18H17N3O3: C: 66.87%; H: 5.26%; N: 13.00%; Found: C: 
66.50%; H: 5.30%; N: 12.79%. 
 
4.2.2.20. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-phenylethylamide (24).  
Yield: 67%. IR (KBr): 3203 (m, NH); 1666 (s, CO); 1326 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 8.91 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.38 (d, 1H, JH5-H6=8.8 Hz, H5); 8.23 (s, 1H, H8); 7.82 
(d, 1H, H6); 7.35-7.21 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-
Ph); 2.59 (s, 3H, CH3-C7); 2.23 (s, 3H, CH3-C3). Calculated analysis for C19H19N3O3: C: 67.65%; H: 
5.64%; N: 12.46%; Found: C: 67.28%; H: 5.87%; N: 12.16%. 
 
4.2.2.21. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-phenylethylamide 
(25).  Yield: 61%. IR (KBr): 3203 (m, NH); 1663 (s, CO); 1328 (s, N
+
O
-
). 
1
H RMN (400 MHz, 
DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.26 (s, 1H, H5), 8.23 (s, 1H, H8); 7.36-7.22 
(m, 5H, Ph); 3.61-3.56 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.50 (s, 6H, CH3-
C6+CH3-C7); 2.22 (s, 3H, CH3-C3). Calculated analysis for C20H21N3O3: C: 68.38%; H: 5.98%; N: 
11.97%; Found: C: 68.47%; H: 6.08%; N: 11.75% 
 
4.2.2.22. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-
phenylethylamide (26).  Yield: 36%. IR (KBr): 3180 (m, NH); 1665 (s, CO); 1329 (s, N
+
O
-
). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.40 (d, 1H, JH5-H6=9.5 Hz, 
H5); 7.77 (d, 1H, JH8-H6=2.5 Hz, H8); 7.60 (dd, 1H, H6); 7.36-7.23 (m, 5H, Ph); 3.99 (s, 3H, OCH3); 
3.61-3.56 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.02 Hz, CH2-Ph); 2.22 (s,  3H, CH3). Calculated 
analysis for C19H19N3O4: C: 64.59%; H: 5.38%; N: 11.90%. Found: C: 64.46%; H: 5.44%; N: 
11.66% 
 
4.2.2.23. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-phenylethylamide 
(27).  Yield: 44%. IR (KBr): 3224 (m, NH); 1667 (s, CO); 1324 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm: 8.91 (t, 1H, JNH-CH2=5.2 Hz, NH); 8.49 (d, 1H, JH5-H6=9.2 Hz, H5); 8.45 (d, 1H, 
JH8-H6=2.3 Hz, H8); 8.03 (dd, 1H, H6); 7.36-7.29 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 
JCH2-Ph=7.1 Hz, 2H, CH2-Ph); 2.23 (s, 3H, CH3). Calculated analysis for C18H16ClN3O3: C: 60.42%; 
H: 4.47%; N: 11.75%; Found: C: 60.14%; H: 4.50%; N: 11. 58% 
 
4.2.2.24. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-
phenylethylamide (28).  Yield: 38%. IR (KBr):  3231 (m, NH); 1666 (s, CO); 1322 (s, N
+
O
-
). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 88.93 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.66 (s, 1H, H5); 8.64 (s, 
1H, H8); 7.34-7.22 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.0 Hz, CH2-Ph); 
2.24 (s, 3H, CH3-C3). Calculated analysis for C18H15Cl2N3O3: C: 55.10%; H: 3.82%; N: 10.71%; 
Found: C: 54.70%; H: 3.92%; N: 10.44% 
 
4.2.2.25. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-phenylethylamide 
(29).  Yield: 77%. IR (KBr): 3231 (m, NH); 1669 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm:  8.92 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.56 (dd, 1H, JH5-H6=9.5 Hz, JH5-F=5.2 Hz, 
H5); 8.20 (dd, 1H, JH8-F=8.8 Hz, JH8-H6=2.5 Hz, H8); 7.91 (ddd, 1H, JH6-F=8.0 Hz, H6); 7.36-7.23 
(m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.0 Hz, CH2-Ph); 2.23 (s, 3H, CH3). 
Calculated analysis for C18H16FN3O3: C: 63.34%; H: 4.69%; N: 12.32%; Found: C: 63.02%; H: 
4.80%; N: 12.32%. 
 
4.2.2.26. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-
phenylethylamide (30). Yield: 39%. IR (KBr): 3240 (m, NH); 1668 (s, CO); 1332 (s, N
+
O
-
). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.53-8.47 (m, 2H, H6+H8); 
7.36-7.20 (m, 5H, Ph); 3.61-3.56 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.24 (s, 
3H, CH3). Calculated analysis for C18H15F2N303: C: 60.17%; H: 4.18%; N: 11.70%; Found: C: 
60.32%; H: 4.34%; N: 11.87%. 
 
4.2.2.27. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-
phenylethylamide (31). Yield: 9%. IR (KBr): 3243 (m, NH); 1669 (s, CO); 1323 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.4 Hz, NH); 8.74 (s, 1H, H8); 8.66 (d, 1H, JH5-
H6=9.2 Hz, H5); 8.27 (d, 1H, H6); 7.33-7.31 (m, 5H, Ph); 3.58-3.63 (m, 2H, NH-CH2); 2.88 (t, JCH2-
Ph=7.0 Hz, 2H, CH2-Ph); 2.27 (s, 3H, CH3). Calculated analysis for C19H16F3N3O3: C: 58.31%; H: 
4.09%; N: 10.74%; Found: C: 58.10%; H: 4.025; N: 10.76%. 
 
4.2.2.28. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-methoxyphenyl)-
ethylamide (32). Yield: 10,90%.  IR (KBr): 3212 (m, NH); 1670 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.88 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.48-8.46 (m, 2H, H5+H8); 8.00-
7.98 (m, 2H, H6+H7); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’), 3.72 (s, 3H, 
OCH3); 3.57-3.52 (m, 2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.28 (s, 3H, CH3). 
Calculated analysis for C19H19N3O4: C: 64.59%; H: 5.38%; N: 11.90%; Found: C: 64.25%; H: 
5.24%; N: 11.81% 
 
4.2.2.29. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-(4-methoxyphenyl)-
ethylamide (33).  Yield: 19.11%. IR (KBr): 3209 (m, NH); 1666 (s, CO); 1329 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.88 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.38 (d, 1H, JH5-H6=8.9 Hz, H5); 
8.26 (s, 1H, H8); 7.81 (d, 1H, H6); 7.22 (d, 2H, JH2’-H3’=8.2 Hz, H2’+H6’); 6.89 (d, 2H, H3’+H5’), 3.72 
(s, 3H, OCH3); 3.56-3.52 (m, 2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.0 Hz, CH2-Ph); 2.58 (s, 3H, CH3-
C7); 2.25 (s, 3H, CH3-C3). Calculated analysis for C20H21N3O4: C: 65.40%; H: 5.72%; N: 11.44%; 
Found: C: 65.62%; H: 5.66%; N: 11.58%. 
 
4.2.2.30. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-(4-methoxyphenyl)-
ethylamide (34).  Yield: 52.94%. IR (KBr): 3203 (m, NH); 1665 (s, CO); 1326 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.26 (s, 1H, H5); 8.22 (s, 1H, H8);  
7.22 (d, 2H, JH2’-H3=8.5 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.73 (s, 1H, OCH3); 3.56-3.51 (m, 2H, 
NH-CH2); 2.79 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.46 (s, 6H, CH3-C7+CH3-C6); 2.25 (s, 3H, CH3-C3). 
Calculated analysis for C21H23N3O4: C: 66.14%; H: 6.04%; N: 11.02%; Found: C: 66.02%; H: 
6.09%; N: 10.99%. 
 
4.2.2.31. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (35).  Yield: 20.97%. IR (KBr): 3221 (m, NH); 1666 (s, CO); 1325 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.89 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.40 (d, 1H, JH5-
H6=9.5 Hz, H5); 7.76 (d, 1H, JH8-H6=2.7 Hz, H8); 7.59 (dd, 1H, H6); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, 
H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.98 (s, 3H, OCH3-C7); 3.72 (s, 3H, OCH3-C4’);  3.57-3.52 (m, 2H, 
NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.22 (s, 3H, CH3). Calculated analysis for 
C20H21N3O5: C: 62.66%; H: 5.48%; N: 10.97%; Found: C: 62.37%; H: 5.66%; N: 10.66% 
 
4.2.2.32. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (36).  Yield: 48.00%. IR (KBr): 3287 (m, NH); 1655 (s, CO); 1328 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.87 (s, 1H, NH); 8.49 (d,1H, JH5-H6=9.3 Hz, H5); 
8.45 (d, 1H, JH8-H6=2.1 Hz, H8); 8.02 (dd, 1H, H6); 7.22 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.88 (d, 
2H, H3’+H5’); 3.73 (s, 3H, OCH3); 3.57-3.52 (m, 2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.0 Hz, CH2-
Ph); 2.26 (s, 3H, CH3). Calculated analysis for C19H18ClN3O4: C: 58.84%; H: 4.65%; N: 10.84%; 
Found: C: 58.62%; H: 4.72%; N: 10.40%. 
 
4.2.2.33. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (37).  Yield: 28.40%. IR (KBr): 3230 (m, NH); 1667 (s, CO); 1324 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.66 (s, 1H, H5); 
8.64 (s, 1H, H8); 7.22 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.72 (s, 1H, OCH3); 
3.57-3.52 (m, 2H, NH-CH2); 2.79 (t, 2H, JCH2-Ph=6.9 Hz, CH2-Ph); 2.26 (s, 3H, CH3). Calculated 
analysis for C19H17Cl2N3O4: C: 54.03%; H: 4.03%; N: 9.95%; Found: C: 53.66%; H: 3.92%; N: 
9.65%. 
 
4.2.2.34. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (38).  Yield: 18.76%. IR (KBr): 3223 (m, NH); 1668 (s, CO); 1330  (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.88 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.56 (dd, 1H JH5-
H6=9.4 Hz, JH5-F=5.2 Hz, H5); 8.20 (dd, 1H, JH8-F=8.8 Hz, JH8-H6=2.8 Hz, H8); 7.94-7.81 (m, 1H, 
H6); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.72 (s, 3H, OCH3); 3.57-3.52 (m, 
2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.28 (s, 3H, CH3). Calculated analysis for 
C19H18FN3O4: C: 61.46%; H: 4.85%; N: 11.32%; Found: C: 61.10%; H: 4.78%; N: 11.54%. 
 
4.2.2.35. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (39).  Yield: 12.75%. IR (KBr): 3242 (m, NH); 1669 (s, CO); 1334 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.48-8.46 (m, 2H, 
H5+H8); 7.22 (d, 2H, JH2’-H3’=8.4 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.76 (s, 3H, OCH3); 3.57-3.52 
(m, 2H, NH-CH2); 2.79 (t, 2H, JCH2-CH2=7.0 Hz, CH2-CH2-Ph); 2.26 (s, 3H, CH3). Calculated 
analysis for C19H17F2N3O4: C: 58.61%; H: 4.37%; N: 10.80%Found: C: 58.86%; H: 4.435%; N: 
10.55%. 
 
4.2.2.36. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (40).  Yield: 6.79%. IR (KBr): 3243 (m, NH); 1669 (s, CO); 1324 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.74 (s, 1H, H5); 
8.66 (d, 1H, JH8-H6=1.8 Hz, H8); 8.27 (dd, 1H, JH6-H5=9.1 Hz, H6); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, 
H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.71 (s, 3H, OCH3); 3.58-3.53 (m, 2H, NH-CH2), 2.80 (t, 2H, JCH2-
Ph=7.0 Hz, CH2-Ph); 2.22 (s, 3H, CH3). Calculated analysis for C20H18F3N3O4: C: 57.01%; H: 
4.28%; N: 9.98%; Found: C: 57.33%; H: 4.22%; N: 9.88%. 
 
4.3. General procedure of anti-tuberculosis activity 
 
In vitro evaluation of the anti-tuberculosis activity was carried out at the GWL Hansen’s Disease 
Center within the Tuberculosis Antimicrobial Acquisition & Coordinating Facility (TAACF) 
screening program for the discovery of novel drugs for the treatment of tuberculosis. Under the 
direction of the U.S. National Institute of Allergy and Infectious Disease (NIAID), the Southern 
Research Institute coordinates the overall program. The purpose of the screening program is to 
provide a resource whereby new experimental compounds can be tested for their capability to 
inhibit the growth of virulent M.Tb.
25
 
 
4.3.1. Determination of growth inhibition percentage via MABA 
 
The initial screen is conducted against M.Tb. H37Rv (ATCC 27294) in BACTEC 12B medium 
using the Microplate Alamar Blue Assay (MABA).
26
 Compounds exhibiting fluorescence were 
tested in the BACTEC 460-radiometric system. Compounds effecting <90% inhibition in the 
primary screen (MIC >6.25 g/mL) were not further evaluated.  
 
4.3.2. Determination of minimum inhibitory concentration (MIC) via MABA 
 
Compounds demonstrating at least 90% inhibition in the primary screen were re-tested against 
M.Tb. H37Rv at lower concentrations in order to determine the actual minimum inhibitory 
concentration (MIC) in the MABA. The MIC was defined as the lowest concentration effecting a 
reduction in fluorescence of 90% relative to controls. Rifampicin was used as the reference 
compound (RIF 0.015-0.125 µg/mL). 
 
4.3.3. Determination of cytotoxicity in VERO cells 
 
Compounds are screened by serial dilution to assess toxicity to a VERO cell line at 
concentrations less than or equal to 6.25 µg/ml or 10 times the MIC for M.Tb. H37Rv if sample 
solubility in culture medium permits. After 72 hours of exposure, viability is assessed on the basis 
of cellular conversion of MTT into a formazan product using the Promega CellTiter 96 Non-
radioactive Cell Proliferation Assay.  RIF was used as the reference compound (RIF IC50>100 
µg/mL). 
 
4.3.4. Determination of selectivity index (SI) 
 
The selectivity index (SI) is defined as the ratio of the measured IC50 in VERO cells to the MIC 
for M.Tb. H37Rv. In general, requirements for moving a compound into in vivo testing include: 
MIC ≤ 6.25 µg/mL and SI ≥ 10 (occasionally lower). RIF was used as the reference compound (RIF 
SI>800). 
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 Abstract: 
 
Mycobacterium tuberculosis (M.Tb) is a bacillus capable of causing a chronic and fatal 
condition in humans known as tuberculosis (TB). It is estimated that there are 8 million new cases 
of TB per year and 3.1 million infected people die annually. Thirty-six new amide quinoxaline 1,4-
di-N-oxide derivatives have been synthesized and evaluated as potential anti-tubercular agents, 
obtaining biological values similar to the reference compound, Rifampin. 
 
Key words: anti-tuberculosis agents, quinoxaline 1,4-di-N-oxide derivatives, Mycobacterium 
tuberculosis (M.Tb.), Rifampin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
 
Tuberculosis (TB) is a respiratory disease mainly caused by the bacillus Mycobacterium 
tuberculosis (M.Tb.). It is responsible for 8 million new cases and 3.1 million deaths per year, 
mostly occurring in developing countries, although there are over 400.000 new cases annually in 
industrialized countries. As infection with human immunodeficiency virus (HIV) becomes more 
prevalent, tuberculosis is becoming a serious problem in developed countries as well
1
, as can be 
observed in Figure 1. Of particular concern is the development of drug-resistant forms of the 
disease, Multidrug-Resistant Tuberculosis (MDR-TB) and Extensively Drug-Resistant Tuberculosis 
(XDR-TB). These forms of the disease are more often fatal and are difficult and expensive to treat. 
It has been estimated that up to 50 million people are infected with drug-resistant forms of TB.
2,3
 
Because of the problems related to MDR-TB and XDR-TB, it is necessary to develop new, 
potent, fast-acting anti-tuberculosis drugs with low-toxicity profiles that can be given in conjunction 
with drugs used to treat HIV infections.
4,5
 New drugs and improved delivery methods will be 
integral parts of a strategy to fully control future outbreaks of TB, particularly MDR-TB, which has 
severely challenged the limited number of effective treatment options.
3
 
 
Figure 1:  
 
Quinoxaline and quinoxaline 1,4-di-N-oxide derivatives display excellent biological activities 
(antiviral, anticancer, antibacterial, anti-parasitic… etc.) with application in many different 
therapeutic areas.
6-8
 As a result of the anti-tuberculosis research project, our group has published 
several papers in which synthesis and biological activity assessments of a large number of 
quinoxaline and quinoxaline 1,4-di-N-oxide derivatives have been described
9-17
,
 
identifying some 
structural requirements for optimal activity.
13-19
 
A few years ago, a group of thirty-one 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide 
derivatives were prepared and tested against M.Tb., obtaining some interesting results.
13
 Three of 
these compounds presented enough selectivity and good results in macrophage assay so as to merit 
continuation of their study. With the aim of improving the previous results, new amide quinoxaline 
1,4-di-N-oxide derivatives have been synthesized and evaluated as potential anti-tubercular agents, 
obtaining excellent results as can be observed in this report.  
 
2. Results and Discussion 
 
Thirty-six new 1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid aryl amide derivatives 
were prepared through the synthetic route as follows: 
First, the starting benzofuroxanes (BFX) were obtained by previously described methods.
20,21
 
Next, the initial β-acetoacetamide derivatives (1-4) were synthesized through acetoacetylation of 
corresponding aryl amines by diketene, using methanol as the solvent as shown in Scheme 1.
22
  
 
Scheme 1.  
 
Finally, the new 1,4-di-N-oxide-quinoxaline derivatives were prepared using a variation of the 
Beirut reaction, where the different BFX react with the corresponding β-acetoacetamide in the 
presence of calcium chloride and ethanolamine as catalysts (Scheme 2).
23
 
 
Scheme 2. 
 
Quinoxaline derivatives were un-substituted or substituted in positions 6 and 7 by chloro, fluoro 
or trifluoromethyl moiety as electron-withdrawing groups and by methyl or methoxy moiety as 
electron-releasing groups. When the new quinoxalines were prepared from monosubstituted-BFX, 
mixtures of positional isomers were obtained. Generally, it could be observed that the 7-substituted 
isomer prevailed over 6-substituted isomer.
24
  
Table 1 summarizes the biological values of the synthesized compounds. The primary screening 
level determinates the activity of the compounds against M.Tb. in H37Rv strain. Samples showing a 
percentage of TB growth inhibition greater than or equal to 90% are considered active and 
therefore, move on to the secondary screening. Active compounds are tested in order to determine 
the actual minimum inhibitory concentration (MIC), and simultaneously cytotoxicity (IC50) in 
VERO cells is evaluated. Next, the MIC and IC50 values are formed into a ratio termed Selectivity 
Index (SI).  If the SI level is 10 or greater, a compound is considered active at the second level. 
 
Table 1:  
 
3. Conclusions 
 
Thirty-six new 1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid aryl amide derivatives 
were synthesized using a variation of the Beirut reaction. Thirty-four of these compounds were 
evaluated against M.Tb. in H37Rv strain; all of them showed a TB growth inhibition percentage 
greater than or equal to 90%.  These compounds were considered active at first level and moved on 
to the secondary screening, where the actual minimum inhibitory concentration (MIC) in H37Rv 
strain and cytotoxicity (IC50) in VERO cells were determinated. In this case, twenty three of the 
twenty-six evaluated derivatives, showed a SI greater to 10, being considered active at the second 
level.  
The compounds 10 and 27 were identified as the most interesting derivatives, with great 
antitubercular activity and low values of cytotoxicity as observed by their SI values (Table 1). The 
derivatives 9, 13, 28, 29, 36 and 38 have also shown very good results. Some structure-activity 
relationships could be established. Looking at the values of compounds 9-13, 20-22, 27-31 and 36-
40, it can be said that, in general, the introduction of an electron-withdrawing substituent in the 
quinoxaline ring results in an increment in the antitubercular activity of the derivatives. On the 
contrary, the insertion of an electro-releasing moiety results in a reduction of this activity as can be 
observed by the results obtained for the compounds 6-8, 15-17, 24-26 and 33-35. Comparing the 
cytotoxicity data of the derivatives 5 vs 14, 6 vs 15, 11 vs 20, 13 vs 22, 24 vs 33, 23 vs 32, 27 vs 36 
and 29 vs 38 it can be concluded that the substitution of the para position of the benzene ring with a 
methoxy group increases the cytotoxicity of the compounds. Finally, looking at the values of the 
compounds 10 vs 28 and 13 vs 31, it can be observed that lengthening the aliphatic chain can also 
result in a greater value of cytotoxicity.  
Taking into account the SI values shown in Table 1, it can be said that these values are similar to 
the reference compound, Rifampin (RIF). In conclusion, the potency, selectivity, and low 
cytotoxicity of these compounds make them valid leads for synthesizing new compounds that 
possess better activity. 
 
4. Experimental Section 
 
4.1. General Remarks 
 
All of the synthesized compounds were chemically characterized by thin layer chromatography 
(TLC), infrared (IR), proton nuclear magnetic resonance (
1
H-NMR) and elemental microanalyses 
(CHN). 
Alugram SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co. KG., Düren, 
Germany) was used for TLC, and Silica gel 60 (0.040-0.063 mm, Merck) was used for Flash 
Column Chromatography. The 
1
H MNR spectra were recorded on a Bruker 400 Ultrashield 
instrument (400 MHz), using TMS as internal standard and with DMSO-d6 or CDCl3 as solvents; 
the chemical shifts are reported in ppm (δ) and coupling constant (J) values are given in Hertz (Hz). 
Signal multiplicities are represented by: s (singlet), bs (broad singlet), d (doublet), dd (double 
doublet), ddd (double double doblet), t (triplet), q (quadruplet) and m (multiplet). The IR spectra 
were recorded on a Nicolet Nexus FTIR (Thermo, Madison, USA) in KBr pellets. Elemental 
microanalyses were obtained on a CHN-900 Elemental Analyzer (Leco, Tres Cantos, Spain) from 
vacuum-dried samples. The analytical results for C, H and N, were within ± 0.4 of the theoretical 
values. Chemicals were purchased from Panreac Química S.A. (Barcelona, Spain), Sigma-Aldrich 
Química, S.A. (Alcobendas, Spain), Acros Organics (Janssen Pharmaceuticalaan, Geel, Belgium) 
and Lancaster (Bischheim-Strasbourg, France). 
 
4.2. General procedure of synthesis 
 
4.2.1. Synthesis of β-acetoacetamide derivatives (1-4) 
 
The corresponding aryl amines (20.0 mmol) were diluted in methanol (20.0 mL) in N2 
atmosphere and cooled in ice bath until 0ºC. Next, diketene (22.0 mmol) was added dropwise and 
the reaction was stirred for 2-3h. The obtained residue was precipitated with cold diethyl ether and 
filtered in order to obtain a red-brown solid. The compound was used without further purification. 
 
4.2.1.1. N-benzyl-3-oxobutanamide (1). Yield 25%. IR (KBr): 3318 (m, NH); 1617 (s, CO); 
1540 (s, CO). 
1
H MNR (400 MHz, CDCl3) δ ppm: 9.52 (bs, 1H, NH); 7.33-7.21 (m, 5H, Ph); 4.56-
4.35 (m, 4H, CH2-NH-CO-CH2-CO); 1.89 (s, 3H, CH3). 
 
4.2.1.2. N-(4-methoxybenzyl)-3-oxobutanamide (2). Yield 77%. IR (KBr): 3317 (s, NH); 
1619 (s, CO); 1539 (s, CO). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.46 (t, 1H, JNH-CH2=5.0 Hz, 
NH); 7.20 (d, 2H, JH2-H3=8.6 Hz, H2+H6); 6.89 (d, 2H, H3+H5); 4.22 (d, 2H, CH2-NH); 3.73 (s, 2H, 
CO-CH2-CO); 3.35 (s, 3H, OCH3); 2.15 (s, 3H, CH3). 
 
4.2.1.3. 3-Oxo-N-phenethylbutanamide (3). Yield 46%. IR (KBr): 3257 (s, NH); 1714 (s, 
CO); 1644 (s, CO). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.13 (t, 1H, JNH-CH2=5.2 Hz, NH); 
7.34-7.14 (m, 5H, Ph); 3.33-3.30 (m, 2H, CH2-NH); 3.27 (s, 2H, CO-CH2-CO); 2.72 (t, 2H, JCH2-
Ph=7.2 Hz, CH2-Ph); 2.10 (s, 3H, CH3). 
 
4.2.1.4. N-(4-methoxyphenethyl)-3-oxobutanamide (4). Yield 56%. IR (KBr): 3263 (m, NH); 
1719 (m, CO); 1641 (s, CO). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.10 (t, 1H, JNH-CH2=5.3 Hz, 
NH); 7.13 (d, 2H, JH2-H3=8.4 Hz, H2+H6); 6.85 (d, 2H, H3+H5); 3.72 (s, 3H, OCH3); 3.32-3.18 (m, 
4H, CH2-NH-CO-CH2-CO); 2.65 (t, 2H, JCH2-Ph=7.3 Hz, CH2-Ph); 2.10 (s, 3H, CH3). 
 
4.2.2. Synthesis of 1,4-di-N-oxide-3-methyl-quinoxaline-2-carboxylic acid aryl amide derivatives 
(5-40) 
 
The corresponding BFX (1.0 mmol) and the corresponding β-acetoacetamide (1.2 mmol) were 
dissolved in the minimum amount of methanol. Next, calcium chloride (0.1 mmol) and 
ethanolamine (5 drops) were added as catalyst, as described by Stumm and Niclas.
23
 The reaction 
was stirred at room temperature from 1 to 5 hours, filtered and washed with cold ethanol. The solid 
was dissolved in dichloromethane and quenched with water. The organic phase was dried with 
sodium sulphate and filtered. The solvent was removed in vacuo and precipitated with cold diethyl 
ether in order to obtain a yellow solid. The solid was purified by column chromatography, if 
necessary. 
 
4.2.2.1. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (5). Yield: 
47%.  IR (KBr): 3218 (m, NH); 1677 (s, CO); 1324 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ 
ppm: 9.36 (t, 1H, JNH-CH2=5.8 Hz, NH); 8.52-8.49 (m, 2H, H5+H8); 8.02-7.95 (m, 2H, H6+H7); 7.46-
7.28 (m, 5H, Ph); 4.57 (d, 2H, CH2); 2.43 (s, 3H, CH3). Calculated analysis for C17H15N3O3: C: 
66.02%; H: 4.85%; N: 13.59%; Found: C: 66.02%; H: 4.96%; N: 13.69%. 
 
4.2.2.2. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-benzylamide (6).  
Yield: 1.3%. IR (KBr): 3222 (m, NH); 1661 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 9.37 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.39 (d, 1H, JH5-H6=8.8 Hz, H5); 8.31 (d, 1H, JH8-
H6=1.5 Hz, H8); 7.83 (dd, 1H, H6); 7.46-7.28 (m, 5H, Ph); 4.56 (d, 2H, CH2); 2.59 (s, 3H, CH3-C3); 
2.41 (s, 3H, CH3-C7). Calculated analysis for C18H17N3O3: C: 66.87%; H: 5.26%; N: 13.00%; Found: 
C: 66.79%; H: 5.26%; N: 12.91%. 
 
4.2.2.3. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-benzylamide (7).  
Yield: 21%. IR (KBr): 3199 (m, NH); 1679 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, CDCl3) δ 
ppm: 8.94 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.05 (s, 1H, H5); 7.98 (s, 1H, H8); 7.49-7.34 (m, 5H, Ph); 
4.67 (d, 2H, CH2); 2.65 (s, 3H, CH3-C3); 2.51 (s, 3H, CH3-C7); 2.48 (s, 3H, CH3-C6). Calculated 
analysis for C19H19N3O3: C: 67.66%; H: 5.64%; N: 12.46%; Found: C: 67.89%; H: 5.50%; N: 
12.45%. 
 
4.2.2.4. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (8).  
Yield: 8%. IR (KBr): 3276 (m, NH); 1655 (s, CO); 1323 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) 
δ ppm: 9.37 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.42 (d, 1H, JH5-H6=9.5 Hz, H5); 7.81 (d, 1H, JH8-H6=2.5 
Hz, H8); 7.60 (dd, 1H, H6); 7.47-7.28 (m, 5H, Ph); 4.56 (d, 2H, CH2); 4.00 (s, 3H, OCH3); 2.40 (s, 
3H, CH3). Calculated analysis for C18H17N3O4: C: 63.53%; H: 5.00%; N: 12.35%. Found: C: 
63.92%; H: 5.05%; N: 12.48%. 
 
4.2.2.5. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (9).  
Yield: 35%. IR (KBr): 3235 (m, NH); 1669 (s, CO); 1321 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 8.55-8.52 (m, 2H, H5+H8); 8.49 (t, 1H, JNH-CH2=5.7 Hz, NH); 7.81 (dd, 1H, JH6-H5=9.2 
Hz, JH6-H8=2.2 Hz, H6); 7.45-7.32 (m, 5H, Ph); 4.74 (d, 2H, CH2); 2.79 (s, 3H, CH3). Calculated 
analysis for C17H14ClN3O3: C: 59.38%; H: 4.07%; N: 12.23%; Found: C: 59.06%; H: 4.19%; N: 
12.13%. 
 
4.2.2.6. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide 
(10).  Yield: 61%. IR (KBr):  3274 (m, NH); 1649 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm: 8.72 (s, 1H, H5); 8.68 (s, 1H, H8); 8.41(t, 1H, JNH-CH2=5.8 Hz, NH); 7.44-7.32 
(m, 5H, Ph); 4.74 (d, 2H, CH2); 2.79 (s, 3H, CH3). Calculated analysis for C18H15Cl2N3O4: C: 
54.11%; H: 3.44%; N: 11.14%; Found: C: 54.08%; H: 3.38%; N: 10.87%. 
 
4.2.2.7. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-benzylamide (11).  
Yield: 45%. IR (KBr): 3300 (m, NH); 1671 (s, CO); 1323 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm:  8.61 (dd, 1H, JH5-H6=9.5 Hz, JH5-F=5.0 Hz, H5); 8.52 (d, 1H, JNH-CH2=5.7 Hz, NH); 8.19 
(dd, 1H, JH8-F=8.5 Hz, JH8-H6=2.7 Hz, H8); 7.62 (ddd, 1H, JH6-F=7.3 Hz,  H6); 7.46-7.28 (m, 5H, 
Ph); 4.74 (d, 2H, CH2); 2.77 (s, 3H, CH3). Calculated analysis for C17H14FN3O3: C: 62.37%; H: 
4.28%; N: 12.84%; Found: C: 62.28%; H: 4.32%; N: 12.96%.     
 
4.2.2.8. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-benzylamide 
(12).  Yield: 38%. IR (KBr): 3292 (m, NH); 1670 (s, CO); 1529 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6): 9.38 (t, 1H, JNH-CH2=6.0 Hz, NH); 8.59-8.48 (m, 2H, H5+H8); 7.46-7.26 (m, 5H, Ph); 
4.56 (d, 2H, CH2); 2.42 (s, 3H, CH3). Calculated analysis for C17H13F2N3O3: C: 59.13%; H: 3.77%; 
N: 12.17%; Found: C: 59.36%; H: 3.62%; N: 11.90% 
 
4.2.2.9. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-
benzylamide (13).  Yield: 28%. IR (KBr): 3294(m, NH);  1670(s, CO); 1323 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.92 (d, 1H, JH8-H6=1.7 Hz, H8); 8.70 (d, 1H, JH5-H6=9.0 Hz, H5); 
8.38 (bs, 1H, NH); 8.03 (dd, 1H, H6); 7.45-7.32 (m, 5H, Ph); 4.75 (d, 2H, CH2); 2.82 (s, 3H, CH3). 
Calculated analysis for C18H14F3N3O3: C: 57.29%; H: 3.71%; N: 11.14%; Found: C: 57.25%; H: 
3.62%; N: 11.15%. 
 
4.2.2.10. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-methoxybenzyl)-amide 
(14). Yield: 82%.  IR (KBr): 3174 (m, NH); 1674 (f, CO); 1329 (f, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm: 9.26 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.52-8.50 (m, 2H, H8+H5); 8.02-7.95 (m, 2H, 
H6+H7); 7.37 (d, 2H, JH2´-H3´=8.7 Hz, H2´+H6´); 6.95 (d, 2H, H3´+H5´); 4.49 (d, 2H, CH2); 3.76 (s, 
3H, OCH3); 2.42 (s, 3H, CH3). Calculated analysis for C18H17N3O4: C: 63.71%; H: 5.05%; N: 
12.38%; Found: C: 63.43%; H: 5.11%; N: 12.03% 
 
4.2.2.11. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-(4-methoxybenzyl)-
amide (15).  Yield: 71%. IR (KBr): 3206 (m, NH); 1674 (f, CO); 1326 (f, N
+
O). 
1
H MNR (400 
MHz, DMSO-d6) δ ppm: 9.27 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.39 (d, 1H, JH5-H6=8.8 Hz, H5); 8.30 (s, 
1H, H8); 7.82 (dd, 1H, JH6-H8=1.7 Hz, H6); 7.36 (d, 2H, JH2´-H3´=8.5 Hz, H2´+H6´), 6.94 (d, 2H, 
H3´+H5´), 4.48 (d, 2H, CH2), 3.76 (s, 3H, OCH3), 2.59 (s, 3H, CH3-C7), 2.39 (s, 3H, CH3-C3). 
Calculated analysis for C19H19N3O4: C: 64.58%; H: 5.42%; N: 11.89 %; Found: C: 64.83%; H: 
5.61%; N: 11.50%. 
 
4.2.2.12. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-(4-methoxybenzyl)-
amide (16).  Yield: 64%. IR (KBr): 3210 (m, NH); 1677 (f, CO); 1332 (f, N
+
O).
 1
H RMN (400 
MHz, DMSO-d6) δ ppm: 9.28 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.27 (s, 1H, H5); 8.25 (s, 1H, H8); 7.37 
(d, 2H, JH2´-H3’=8.5 Hz, H2´+H6´); 6.94 (d, 2H, H3´+H5´); 4.48 (d, 2H, CH2); 3.76 (s, 3H, OCH3); 
2.50 (s, 6H, CH3-C6+CH3-C7); 2.39 (s, 3H, CH3-C3). Calculated analysis for C20H21N3O4: C: 65.38%; 
H: 5.76%; N: 11.44%; Found: C: 65.09%; H: 5.62%; N: 11.63%.  
 
4.2.2.13. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (17).  Yield: 79%. IR (KBr): 3283 (m, NH); 1652 (f, CO); 1329 (f, N
+
O). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 9.28 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.40 (d, 1H, JH5-H6=9.5 Hz, 
H5); 7.79 (d, 1H, JH8-H6=2.6 Hz, H8); 7.59 (dd, 1H, H6); 7.37 (d, 2H, JH2´-H3´=8.5 Hz, H2´+H6´); 6.94 
(d, 2H, H3’+H5’); 4.48 (d, 2H, CH2), 3.99 (s, 3H, OCH3-C7), 3.75 (s, 3H, OCH3-C4’), 2.38 (s, 3H, 
CH3). Calculated analysis for C19H19N3O5: C: 61.78%; H: 5.18%; N: 11.38%; Found: 61.58%; H: 
5.21%; N: 11.32%. 
 
4.2.2.14. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (18).  Yield: 30%. IR (KBr): 3270 (m, NH); 1654 (f, CO); 1330 (f, N
+
O).
 1
H 
MNR (400 MHz, DMSO-d6): 9.27 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.53-8.47 (m, 2H, H5+H8); 8.03 
(dd, 1H, JH6-H5=9.2 Hz, JH6-H8=2.3 Hz, H6); 7.36 (d, 2H, JH2´-H3´=8.7 Hz, H2´+H6´); 6.94 (d, 2H, 
H3´+H5´); 4.48 (d, 2H, CH2); 3.76 (s, 3H, OCH3); 2.40 (s, 3H, CH3). Calculated analysis for 
C18H16ClN3O4: C: 57.84%; H: 4.31%; N: 11.24%; Found: C: 57.92%; H: 4.32%; N: 11.22%. 
 
4.2.2.15. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (19).  Yield: 18%. IR (KBr):  3199 (m, NH); 1643 (f, CO); 1323 (f, N
+
O).
 1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 9.30 (t, 1H, JNH-CH2=5.8 Hz, NH); 8.67 (s, 2H, H5+H8); 7.35 
(d, 2H, JH2´-H3’=8.5 Hz, H2´+H6´); 6.94 (d, 1H, H3´+H5´), 4.48 (d, 2H, CH2), 3.75 (s, 3H, OCH3), 
2.40 (s, 3H, CH3). Calculated analysis for C18H15Cl2N3O4: C: 57.84%; H: 4.31%; N: 11.24%; 
Found: C: 57.92%; H: 4.32%; N: 11.22%. 
 
4.2.2.16. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (20).  Yield: 31%. IR (KBr): 3213 (m, NH); 1677 (f, CO); 1323 (f, N
+
O).
 1
H 
MNR (400 MHz, DMSO-d6) δ ppm:  9.28 (t, 1H, JNH-CH2=5.9 Hz, NH); 8.57 (dd, 1H, JH5-H6=9.5 
Hz, JH5-F=5.2 Hz, H5); 8.24 (dd, 1H, JH8-F=8.8, JH8-H6=2.8 Hz, H8); 7.92 (ddd, 1H, JH8-F=8.0 Hz, 
H6); 7.36 (d, 2H, JH2´-H3´=8.7 Hz, H2´+H6´); 6.94 (d, 2H, H3´+H5´); 4.49 (d, 2H, CH2); 3.76 (s, 3H, 
OCH3); 2.40 (s, 3H, CH3). Calculated analysis for C18H16FN3O4: C: 60.50%; H: 4.51%; N: 11.76%; 
Found: C: 60.74%; H: 4.51%; N: 11.73%. 
 
4.2.2.17. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (21).  Yield: 71%. IR (KBr): 3199 (m, NH); 1645 (f, CO); 1333 (f, N
+
O). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 9.29 (t, 1H, JNH-CH2=5.8 Hz, NH); 8.56-8.50 (m, 2H, H5+H8); 
7.36 (d, 2H, JH2´-H3´=8.5 Hz, H2´+H6´); 6.94 (d, 2H, H3´+H5´); 4.48 (d, 2H, CH2); 3.76 (s, 3H, 
OCH3); 2.41 (s, 3H, CH3). Calculated analysis for C18H15F2N3O4: C: 57.60%; H: 4.03%; N: 
11.20%; Found: C: 57.33%; H: 3.91%; N: 11.14%. 
 
4.2.2.18. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-(4-
methoxybenzyl)-amide (22).  Yield: 78%. IR (KBr): 9.88%. IR (KBr): 3276 (m, NH); 1648 (f, CO); 
1133 (f, N
+
O). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 9.29 (t, 1H, JNH-CH2=6.1 Hz, NH); 8.75 (s, 
1H, H5); 8.70-8.69 (m, 1H, H8); 8.32-8.26 (m, 1H, H6); 7.36 (d, 2H, JH2´-H3´=8.5 Hz, H2´+H6´); 6.95 
(d, 2H, H3´+H5´); 4.49 (d, 2H, CH2); 3.76 (s, 3H, OCH3); 2.44 (s, 3H, CH3). Calculated analysis for 
C19H16F3N3O4: C: 56.02%; H: 3.93%; N: 10.32%; Found: C: 56.39%; H: 3.85%; N: 10.44%. 
 
4.2.2.19. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-phenylethylamide (23). 
Yield: 55%. IR (KBr): 3213 (m, NH); 1668 (s, CO); 1334 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 8.91 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.50-8.45 (m, 2H, H5+H8); 8.02-7.95 (m, 2H, H6+H7); 
7.35-7.22 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph), 2.25 (s, 
3H, CH3). Calculated analysis for C18H17N3O3: C: 66.87%; H: 5.26%; N: 13.00%; Found: C: 
66.50%; H: 5.30%; N: 12.79%. 
 
4.2.2.20. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-phenylethylamide (24).  
Yield: 67%. IR (KBr): 3203 (m, NH); 1666 (s, CO); 1326 (s, N
+
O
-
). 
1
H MNR (400 MHz, DMSO-
d6) δ ppm: 8.91 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.38 (d, 1H, JH5-H6=8.8 Hz, H5); 8.23 (s, 1H, H8); 7.82 
(d, 1H, H6); 7.35-7.21 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-
Ph); 2.59 (s, 3H, CH3-C7); 2.23 (s, 3H, CH3-C3). Calculated analysis for C19H19N3O3: C: 67.65%; H: 
5.64%; N: 12.46%; Found: C: 67.28%; H: 5.87%; N: 12.16%. 
 
4.2.2.21. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-phenylethylamide 
(25).  Yield: 61%. IR (KBr): 3203 (m, NH); 1663 (s, CO); 1328 (s, N
+
O
-
). 
1
H RMN (400 MHz, 
DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.26 (s, 1H, H5), 8.23 (s, 1H, H8); 7.36-7.22 
(m, 5H, Ph); 3.61-3.56 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.50 (s, 6H, CH3-
C6+CH3-C7); 2.22 (s, 3H, CH3-C3). Calculated analysis for C20H21N3O3: C: 68.38%; H: 5.98%; N: 
11.97%; Found: C: 68.47%; H: 6.08%; N: 11.75% 
 
4.2.2.22. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-
phenylethylamide (26).  Yield: 36%. IR (KBr): 3180 (m, NH); 1665 (s, CO); 1329 (s, N
+
O
-
). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.40 (d, 1H, JH5-H6=9.5 Hz, 
H5); 7.77 (d, 1H, JH8-H6=2.5 Hz, H8); 7.60 (dd, 1H, H6); 7.36-7.23 (m, 5H, Ph); 3.99 (s, 3H, OCH3); 
3.61-3.56 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.02 Hz, CH2-Ph); 2.22 (s,  3H, CH3). Calculated 
analysis for C19H19N3O4: C: 64.59%; H: 5.38%; N: 11.90%. Found: C: 64.46%; H: 5.44%; N: 
11.66% 
 
4.2.2.23. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-phenylethylamide 
(27).  Yield: 44%. IR (KBr): 3224 (m, NH); 1667 (s, CO); 1324 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm: 8.91 (t, 1H, JNH-CH2=5.2 Hz, NH); 8.49 (d, 1H, JH5-H6=9.2 Hz, H5); 8.45 (d, 1H, 
JH8-H6=2.3 Hz, H8); 8.03 (dd, 1H, H6); 7.36-7.29 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 
JCH2-Ph=7.1 Hz, 2H, CH2-Ph); 2.23 (s, 3H, CH3). Calculated analysis for C18H16ClN3O3: C: 60.42%; 
H: 4.47%; N: 11.75%; Found: C: 60.14%; H: 4.50%; N: 11. 58% 
 4.2.2.24. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-
phenylethylamide (28).  Yield: 38%. IR (KBr):  3231 (m, NH); 1666 (s, CO); 1322 (s, N
+
O
-
). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 88.93 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.66 (s, 1H, H5); 8.64 (s, 
1H, H8); 7.34-7.22 (m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.0 Hz, CH2-Ph); 
2.24 (s, 3H, CH3-C3). Calculated analysis for C18H15Cl2N3O3: C: 55.10%; H: 3.82%; N: 10.71%; 
Found: C: 54.70%; H: 3.92%; N: 10.44% 
 
4.2.2.25. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-phenylethylamide 
(29).  Yield: 77%. IR (KBr): 3231 (m, NH); 1669 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR (400 MHz, 
DMSO-d6) δ ppm:  8.92 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.56 (dd, 1H, JH5-H6=9.5 Hz, JH5-F=5.2 Hz, 
H5); 8.20 (dd, 1H, JH8-F=8.8 Hz, JH8-H6=2.5 Hz, H8); 7.91 (ddd, 1H, JH6-F=8.0 Hz, H6); 7.36-7.23 
(m, 5H, Ph); 3.62-3.57 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.0 Hz, CH2-Ph); 2.23 (s, 3H, CH3). 
Calculated analysis for C18H16FN3O3: C: 63.34%; H: 4.69%; N: 12.32%; Found: C: 63.02%; H: 
4.80%; N: 12.32%. 
 
4.2.2.26. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-
phenylethylamide (30). Yield: 39%. IR (KBr): 3240 (m, NH); 1668 (s, CO); 1332 (s, N
+
O
-
). 
1
H 
MNR (400 MHz, DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.53-8.47 (m, 2H, H6+H8); 
7.36-7.20 (m, 5H, Ph); 3.61-3.56 (m, 2H, NH-CH2); 2.87 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.24 (s, 
3H, CH3). Calculated analysis for C18H15F2N303:  C: 60.17%; H: 4.18%; N: 11.70%; Found: C: 
60.32%; H: 4.34%; N: 11.87%. 
 
4.2.2.27. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-
phenylethylamide (31). Yield: 9%. IR (KBr): 3243 (m, NH); 1669 (s, CO); 1323 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.93 (t, 1H, JNH-CH2=5.4 Hz, NH); 8.74 (s, 1H, H8); 8.66 (d, 1H, JH5-
H6=9.2 Hz, H5); 8.27 (d, 1H, H6); 7.33-7.31 (m, 5H, Ph); 3.58-3.63 (m 2H, NH-CH2); 2.88 (t, JCH2-
Ph=7.0 Hz, 2H, CH2-Ph); 2.27 (s, 3H, CH3). Calculated analysis for C19H16F3N3O3: C: 58.31%; H: 
4.09%; N: 10.74%; Found: C: 58.10%; H: 4.025; N: 10.76%. 
 
4.2.2.28. 1,4-Di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-methoxyphenyl)-
ethylamide (32). Yield: 10,90%.  IR (KBr): 3212 (m, NH); 1670 (s, CO); 1328 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.88 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.48-8.46 (m, 2H, H5+H8); 8.00-
7.98 (m, 2H, H6+H7); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’), 3.72 (s, 3H, 
OCH3); 3.57-3.52 (m, 2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.28 (s, 3H, CH3). 
Calculated analysis for C19H19N3O4: C: 64.59%; H: 5.38%; N: 11.90%; Found: C: 64.25%; H: 
5.24%; N: 11.81% 
 
4.2.2.29. 3,7-Dimethyl-1,4-di-N-oxidequinoxaline-2-carboxylic acid 2-(4-methoxyphenyl)-
ethylamide (33).  Yield: 19.11%. IR (KBr): 3209 (m, NH); 1666 (s, CO); 1329 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.88 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.38 (d, 1H, JH5-H6=8.9 Hz, H5); 
8.26 (s, 1H, H8); 7.81 (d, 1H, H6); 7.22 (d, 2H, JH2’-H3’=8.2 Hz, H2’+H6’); 6.89 (d, 2H, H3’+H5’), 3.72 
(s, 3H, OCH3); 3.56-3.52 (m, 2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.0 Hz, CH2-Ph); 2.58 (s, 3H, CH3-
C7); 2.25 (s, 3H, CH3-C3). Calculated analysis for C20H21N3O4: C: 65.40%; H: 5.72%; N: 11.44%; 
Found: C: 65.62%; H: 5.66%; N: 11.58%. 
 
4.2.2.30. 1,4-Di-N-oxide-3,6,7-trimethylquinoxaline-2-carboxylic acid 2-(4-methoxyphenyl)-
ethylamide (34).  Yield: 52.94%. IR (KBr): 3203 (m, NH); 1665 (s, CO); 1326 (s, N
+
O
-
). 
1
H MNR 
(400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.26 (s, 1H, H5); 8.22 (s, 1H, H8);  
7.22 (d, 2H, JH2’-H3=8.5 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.73 (s, 1H, OCH3); 3.56-3.51 (m, 2H, 
NH-CH2); 2.79 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.46 (s, 6H, CH3-C7+CH3-C6); 2.25 (s, 3H, CH3-C3). 
Calculated analysis for C21H23N3O4: C: 66.14%; H: 6.04%; N: 11.02%; Found: C: 66.02%; H: 
6.09%; N: 10.99%. 
 
4.2.2.31. 1,4-Di-N-oxide-7-methoxy-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (35).  Yield: 20.97%. IR (KBr): 3221 (m, NH); 1666 (s, CO); 1325 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.89 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.40 (d, 1H, JH5-
H6=9.5 Hz, H5); 7.76 (d, 1H, JH8-H6=2.7 Hz, H8); 7.59 (dd, 1H, H6); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, 
H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.98 (s, 3H, OCH3-C7); 3.72 (s, 3H, OCH3-C4’);  3.57-3.52 (m, 2H, 
NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.22 (s, 3H, CH3). Calculated analysis for 
C20H21N3O5: C: 62.66%; H: 5.48%; N: 10.97%; Found: C: 62.37%; H: 5.66%; N: 10.66% 
 
4.2.2.32. 7-Chloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (36).  Yield: 48.00%. IR (KBr): 3287 (m, NH); 1655 (s, CO); 1328 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.87 (s, 1H, NH); 8.49 (d,1H, JH5-H6=9.3 Hz, H5); 
8.45 (d, 1H, JH8-H6=2.1 Hz, H8); 8.02 (dd, 1H, H6); 7.22 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.88 (d, 
2H, H3’+H5’); 3.73 (s, 3H, OCH3); 3.57-3.52 (m, 2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.0 Hz, CH2-
Ph); 2.26 (s, 3H, CH3). Calculated analysis for C19H18ClN3O4: C: 58.84%; H: 4.65%; N: 10.84%; 
Found: C: 58.62%; H: 4.72%; N: 10.40%. 
 
4.2.2.33. 6,7-Dichloro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (37).  Yield: 28.40%. IR (KBr): 3230 (m, NH); 1667 (s, CO); 1324 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.66 (s, 1H, H5); 
8.64 (s, 1H, H8); 7.22 (d, 2H, JH2’-H3’=8.5 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.72 (s, 1H, OCH3); 
3.57-3.52 (m, 2H, NH-CH2); 2.79 (t, 2H, JCH2-Ph=6.9 Hz, CH2-Ph); 2.26 (s, 3H, CH3). Calculated 
analysis for C19H17Cl2N3O4: C: 54.03%; H: 4.03%; N: 9.95%; Found: C: 53.66%; H: 3.92%; N: 
9.65%. 
 
4.2.2.34. 1,4-Di-N-oxide-7-fluoro-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (38).  Yield: 18.76%. IR (KBr): 3223 (m, NH); 1668 (s, CO); 1330  (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.88 (t, 1H, JNH-CH2=5.6 Hz, NH); 8.56 (dd, 1H JH5-
H6=9.4 Hz, JH5-F=5.2 Hz, H5); 8.20 (dd, 1H, JH8-F=8.8 Hz, JH8-H6=2.8 Hz, H8); 7.94-7.81 (m, 1H, 
H6); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.72 (s, 3H, OCH3); 3.57-3.52 (m, 
2H, NH-CH2); 2.80 (t, 2H, JCH2-Ph=7.1 Hz, CH2-Ph); 2.28 (s, 3H, CH3). Calculated analysis for 
C19H18FN3O4: C: 61.46%; H: 4.85%; N: 11.32%; Found: C: 61.10%; H: 4.78%; N: 11.54%. 
 
4.2.2.35. 6,7-Difluoro-1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (39).  Yield: 12.75%. IR (KBr): 3242 (m, NH); 1669 (s, CO); 1334 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.5 Hz, NH); 8.48-8.46 (m, 2H, 
H5+H8); 7.22 (d, 2H, JH2’-H3’=8.4 Hz, H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.76 (s, 3H, OCH3); 3.57-3.52 
(m, 2H, NH-CH2); 2.79 (t, 2H, JCH2-CH2=7.0 Hz, CH2-CH2-Ph); 2.26 (s, 3H, CH3). Calculated 
analysis for C19H17F2N3O4: C: 58.61%; H: 4.37%; N: 10.80%Found: C: 58.86%; H: 4.435%; N: 
10.55%. 
 
4.2.2.36. 1,4-Di-N-oxide-3-methyl-7-trifluoromethylquinoxaline-2-carboxylic acid 2-(4-
methoxyphenyl)-ethylamide (40).  Yield: 6.79%. IR (KBr): 3243 (m, NH); 1669 (s, CO); 1324 (s, 
N
+
O
-
). 
1
H MNR (400 MHz, DMSO-d6) δ ppm: 8.90 (t, 1H, JNH-CH2=5.7 Hz, NH); 8.74 (s, 1H, H5); 
8.66 (d, 1H, JH8-H6=1.8 Hz, H8); 8.27 (dd, 1H, JH6-H5=9.1 Hz, H6); 7.22 (d, 2H, JH2’-H3’=8.6 Hz, 
H2’+H6’); 6.88 (d, 2H, H3’+H5’); 3.71 (s, 3H, OCH3); 3.58-3.53 (m, 2H, NH-CH2), 2.80 (t, 2H, JCH2-
Ph=7.0 Hz, CH2-Ph); 2.22 (s, 3H, CH3). Calculated analysis for C20H18F3N3O4: C: 57.01%; H: 
4.28%; N: 9.98%; Found: C: 57.33%; H: 4.22%; N: 9.88%. 
 
 
 
 
4.3. General procedure of anti-tuberculosis activity 
 
In vitro evaluation of the anti-tuberculosis activity was carried out at the GWL Hansen’s Disease 
Center within the Tuberculosis Antimicrobial Acquisition & Coordinating Facility (TAACF) 
screening program for the discovery of novel drugs for the treatment of tuberculosis. Under the 
direction of the U.S. National Institute of Allergy and Infectious Disease (NIAID), the Southern 
Research Institute coordinates the overall program. The purpose of the screening program is to 
provide a resource whereby new experimental compounds can be tested for their capability to 
inhibit the growth of virulent M.Tb.
25
 
 
4.3.1. Determination of growth inhibition percentage via MABA 
 
The initial screen is conducted against M.Tb. H37Rv (ATCC 27294) in BACTEC 12B medium 
using the Microplate Alamar Blue Assay (MABA).
26
 Compounds exhibiting fluorescence were 
tested in the BACTEC 460-radiometric system. Compounds effecting <90% inhibition in the 
primary screen (MIC >6.25 g/mL) were not further evaluated.  
 
4.3.2. Determination of minimum inhibitory concentration (MIC) via MABA 
 
Compounds demonstrating at least 90% inhibition in the primary screen were re-tested against 
M.Tb. H37Rv at lower concentrations in order to determine the actual minimum inhibitory 
concentration (MIC) in the MABA. The MIC was defined as the lowest concentration effecting a 
reduction in fluorescence of 90% relative to controls. Rifampicin was used as the reference 
compound (RIF 0.015-0.125 µg/mL). 
 
4.3.3. Determination of cytotoxicity in VERO cells 
 
Compounds are screened by serial dilution to assess toxicity to a VERO cell line at 
concentrations less than or equal to 6.25 µg/ml or 10 times the MIC for M.Tb. H37Rv if sample 
solubility in culture medium permits. After 72 hours of exposure, viability is assessed on the basis 
of cellular conversion of MTT into a formazan product using the Promega CellTiter 96 Non-
radioactive Cell Proliferation Assay.  RIF was used as the reference compound (RIF IC50>100 
µg/mL). 
 
4.3.4. Determination of selectivity index (SI) 
 The selectivity index (SI) is defined as the ratio of the measured IC50 in VERO cells to the MIC 
for M.Tb. H37Rv. In general, requirements for moving a compound into in vivo testing include: 
MIC ≤ 6.25 µg/mL and SI ≥ 10 (occasionally lower). RIF was used as the reference compound (RIF 
SI>800). 
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Table 1. 
 
N+
N+
O-
O-
R7
R6
N
H
O
W
n
 
Secondary Screening 
Comp. R7 R6 n W 
MIC(µg/mL)
 
H37Rv
a
 
IC50(µg/mL) 
VERO
b
 
SI 
(IC50/MIC)
c
 
5 H H 1 H 2.606 >100 >38.372 
6 CH3 H 1 H 4.207 >100 >23.77 
7 CH3 CH3 1 H >100 NT NT 
8 OCH3 H 1 H 12.346 NT NT 
9 Cl H 1 H 0.433 >100 >230.94 
10 Cl Cl 1 H <0.2 >100 >500 
11 F H 1 H 1.522 >100 >65.70 
12 F F 1 H 1.727 18.378 10.64 
13 CF3 H 1 H 0.406 >100 >246.30 
14 H H 1 OCH3 2.847 >30 >10.537 
15 CH3 H 1 OCH3 8.903 >30 >3.3696 
16 CH3 CH3 1 OCH3 >100.00 NT NT 
17 OCH3 H 1 OCH3 12.007 NT NT 
18 Cl H 1 OCH3 NT NT NT 
19 Cl Cl 1 OCH3 NT NT NT 
20 F H 1 OCH3 1.508 >30 >19.893 
21 F F 1 OCH3 0.764 16.605 21.734 
22 CF3 H 1 OCH3 0.999 >30 >30.03 
23 H H 2 H 3.048 >100 >32.81 
24 CH3 H 2 H 8.621 >100 >11.60 
25 CH3 CH3 2 H 16.359 NT NT 
26 OCH3 H 2 H 13.657 NT NT 
27 Cl H 2 H <0.2 >100 >500 
28 Cl Cl 2 H <0.195 >30 >153.84 
29 F H 2 H 0.504 >100 >198.41 
30 F F 2 H 0.517 >30 >58.027 
31 CF3 H 2 H 1.153 >30 >26.019 
32 H H 2 OCH3 3.464 >30 >8.6605 
33 CH3 H 2 OCH3 8.852 >30 >3.389 
34 CH3 CH3 2 OCH3 >100.00 NT NT 
35 OCH3 H 2 OCH3 16.866 NT NT 
36 Cl H 2 OCH3 <0.195 >30 >153.84 
37 Cl Cl 2 OCH3 0.454 >30 >66.079 
38 F H 2 OCH3 <0.195 >30 >153.84 
39 F F 2 OCH3 2.058 >30 >14.577 
40 CF3 H 2 OCH3 1.427 >30 >21.023 
RIF - - - - 0.015-0.125 >100 >800 
  
 
 
Table(s)
Legends: 
 
Scheme 1. Synthetic scheme of initial β-acetoacetamide derivatives (1-4). 
 
Scheme 2. Synthetic route of 1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid aryl amide derivatives (5-40). 
 
Table 1: Biological values of compounds (5-40) at secondary screening. 
a
Actual Minimum Inhibitory Concentration in M.Tb. H37Rv strain. 
b
Cytotoxicity in VERO cells. 
c
Selectivity Index. NT: Non 
Tested. 
In the first screening, all of the compounds were evaluated against M.Tb. in H37Rv strain. All of them were active at this level. In 
the secondary screening, the actual minimum inhibitory concentration (MIC) in H37Rv strain and cytotoxicity (IC50) in VERO 
cells were determined. Finally, the SI was calculated and the compounds containing SI level ≥ 10 were considered active at the 
second level. All of these active compounds are highlighted in green in the table, with the most active ones being marked in dark 
green. 
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Legends: 
 
Figure 1: Estimated number of new TB cases, by country, 2007 
[Source: Global Tuberculosis Control WHO REPORT 2009] 
 
Scheme 1. Synthetic scheme of initial β-acetoacetamide derivatives (1-4). 
 
Scheme 2. Synthetic route of 1,4-di-N-oxide-3-methylquinoxaline-2-carboxylic acid aryl amide derivatives (5-40). 
 
Table 1: Biological values of compounds (5-40) at secondary screening. 
a
Actual Minimun Inhibitory Concentration in M.Tb. H37Rv strain. 
b
Citotoxicity in VERO cells. 
c
Selectivity Index. NT: Non 
Tested. 
In the first screening all the compounds were evaluated against M.Tb. in H37Rv strain. All of them were active at this level. In the 
secondary screening the actual minimum inhibitory concentration (MIC) in H37Rv strain and cytotoxicity (IC50) in VERO cells 
were determined. Finally the SI was calculated. 
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